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Natural products provide an unparalleled source of
chemical scaffolds with diverse biological activities
andhaveprofoundly impactedantimicrobial drugdis-
covery. To further explore the full potential of their
chemical diversity, we survey natural products for an-
tifungal, target-specific inhibitors by using a chemi-
cal-genetic approach adapted to the human fungal
pathogen Candida albicans and demonstrate that
natural-product fermentation extracts can bemecha-
nistically annotated according to heterozygote strain
responses. Applying this approach, we report the
discovery and characterization of a natural product,
parnafungin, which we demonstrate, by both bio-
chemical and genetic means, to inhibit poly(A) poly-
merase.Parnafungindisplayspotent andbroadspec-
trum activity against diverse, clinically relevant fungal
pathogens and reduces fungal burden in a murine
model of disseminated candidiasis. Thus, mecha-
nism-of-action determination of crude fermentation
extractsbychemical-geneticprofilingbringsapower-
ful strategy to natural-product-based drug discovery.
INTRODUCTION
Bioactive natural products and their derivatives have historically
served as a major source of therapeutic agents for treating infec-
tious diseases (Newman et al., 2003). This success exploits the
unique characteristics of microbial-produced small molecules,
namely, their immense chemical diversity, intrinsic cell perme-
ability, and bioactive specificity, which are typically absent
from man-made synthetic libraries. Natural products provideChemistry & Biologprivileged chemical scaffolds selected by evolutionary pressures
to interact with a diversity of proteins and other biological tar-
gets, and a reservoir that can be co-opted for drug development
(Yim et al., 2006). Whereas antibiotic discovery has yielded nu-
merous distinct chemical scaffolds (Clardy et al., 2006), existing
antifungal structural classes remain limited despite the medical
need for more efficacious antifungal agents (Petrikkos and
Skiada, 2007).
To discover new antifungal agents from natural sources,
a number of challenges must first be met (Koehn and Carter,
2005). Microbial fermentation extracts are highly complex
mixtures, often containing multiple bioactive components.
Screening unfractionated extracts in biochemical in vitro assays
is complicated by the unknown abundance of any target-specific
inhibitor relative to other components in the mixture that can
cause nonspecific inhibition. Diverse chromatography proce-
dures are available to fractionate extracts; however, their
throughput capacity and application prior to assay screening
remain limited. Also at issue is target selection, the extent of its
biochemical and genetic validation, and its adaptability to high-
throughput screening (HTS). Although all essential genes in
Saccharomyces cerevisiae have been identified (Winzeler et al.,
1999), including many of their orthologs in the human fungal
pathogens Candida albicans (Roemer et al., 2003) and/or Asper-
gillus fumigatus (Hu et al., 2007), it remains unclear which of their
individual gene products are susceptible to chemical inhibition
(Payne et al., 2007). Finally, an important consideration is how
to rapidly dereplicate known and undesirable compounds from
novel chemical entities.
To address these challenges, we and others have turned to
chemical-genetic profiling strategies (Baetz et al., 2004; Giaever
et al., 1999, 2002, 2004; Lum et al., 2004; Rodriguez-Suarez
et al., 2007; Xu et al., 2007). To perform such analyses, strain-
specific bar codes were introduced into a collection of defined
heterozygote deletion mutants to uniquely identify individualy 15, 363–374, April 2008 ª2008 Elsevier Ltd All rights reserved 363
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(Giaever et al., 1999; Shoemaker et al., 1996). When challenged
with a nonlethal concentration of a growth-impairing compound,
individual strains displaying an altered fitness (either reduced or
enhanced) within this population are identified by barcode micro-
array analysis. Surveying chemically induced growth phenotypes
broadly across the genome identifies important aspects of the
inhibitory compound’s mechanism of action (MOA), including its
drug target, import, efflux, and metabolism (Giaever et al., 2004;
Rodriguez-Suarez et al., 2007; Parsons et al., 2006). Screening
natural-product extracts against the viable yeast haploid deletion
set of5000 strains, Parsons et al. (2006) recently demonstrated
that bioactive compounds predicted to share a common MOA
could be identified prior to their purification. Furthermore, these
authors also reported that a crude extract from a marine organism
produced a chemical-genetic profile very similar to that of the
purified compound (Parsons et al., 2006).
Here, we report a new, to our knowledge, natural product
hereby named parnafungin (poly(A) RNA fungin) and its identifi-
cation by C. albicans-based chemical-genetic profiling of crude
fungal fermentation extracts with intrinsic antifungal activity.
Characterization of the parnafungin-containing extract was
based on its distinct MOA profile, wherein multiple heterozygous
mutants corresponding to subunits of the cleavage and poly-
adenylation (C/P) complex displayed hypersensitivity to the
bioactive entity. Bioassay-guided isolation of parnafungin was
achieved by iterative reprofiling of the antifungal fractions and
by confirming that the purified material matched the profile of
the original extract. Mechanistically, the parnafungin profile
most closely matches cordycepin—a known natural-product
inhibitor of polyadenylation (Muller et al., 1977). Demonstration
of parnafungin’s molecular target was achieved by using a
S. cerevisiae cell-free C/P assay, in which 30 mRNA polyadenyla-
tion was preferentially inhibited versus 30 mRNA cleavage. Par-
nafungin also inhibited S. cerevisiae andC. albicans poly(A) poly-
merase (PAP) in vitro activity at nM levels. Independently isolated
parnafungin-resistant C. albicans mutants containing a single
F115I amino acid substitution in PAP1 were also identified and
shown to be sufficient to confer parnafungin resistance in either
PAP allele. Parnafungin displays potent and broad spectrum
activity across multiple fungal pathogens as well as efficacy in
a murine model of disseminated candidiasis.
RESULTS
C. albicans Fitness Test Profiling and MOA
Determination of Bioactive Compounds
in Crude Fermentation Extracts
Recently, we described a C. albicans Fitness Test (CaFT) assay
using a collection of 2900 bar-coded heterozygote deletion
mutants and its utility to predict the MOA of both known and
previously uncharacterized pure compounds, including their cog-
nate target(s), as well as potential resistance mechanisms (Rodri-
guez-Suarez et al., 2007; Xu et al., 2007). Although incomplete in
C. albicans genome coverage (45%), this heterozygote strain set
is significantly biased toward genes experimentally demonstrated
to be required for normal growth of the pathogen (Hu et al., 2007;
Roemer et al., 2003). As such, its composition aids the identification
of essential proteins inhibited by target-specific inhibitors, including364 Chemistry & Biology 15, 363–374, April 2008 ª2008 Elsevier Ltdpurified natural products (e.g., cerulenin, FAS1; tunicamycin, ALG7;
and brefeldin A, SEC7/ARF2) (Roemer et al., 2003).
Expanding on these studies, we first tested whether mecha-
nistically informative CaFT profiles could be obtained by using
a defined bioactive mixture containing varying concentrations
of two natural products. As shown in Figure S1 (see the Sup-
plemental Data available with this article online), equipotent
mixtures of cerulenin combined with tunicamycin, brefeldin A,
or fluconazole produced additive CaFT profiles reflecting the
expected strain depletions of each growth-inhibitory compound.
Mixtures containing an increasing concentration of tunicamycin
or brefeldin A relative to that of cerulenin produced mechanism-
relevant profiles of both activities, but with significantly greater
detection of strain depletions correlating with the major activity
(Figure S1). As expected, mixtures more significantly adjusted
in the ratio between the two activities produced CaFT profiles re-
flective of only the major activity (data not shown).
To examine whether mechanistically relevant profiles could be
obtained from crude natural-product mixtures, unfractionated
extracts prepared from fermentation broths of known producers
of cerulenin, brefeldin A, and tunicamycin were profiled by CaFT
analysis. As shown in Figures 1A–1C, cerulenin (FAS1), brefeldin
A (SEC7, ARF2, and PDR5), and tunicamycin (ALG7 and IAH1)
crude extract profiles were highly related to their corresponding
pure bioactive component. LCMS analysis verified the presence
of cerulenin, brefeldin A, and tunicamycin in the respective
extracts (data not shown). These data demonstrate that CaFT
profiling can identify target-specific inhibitory compounds within
fungal and actinomycete fermentation broths, and that MOA an-
notation of crude extracts could be used to guide their selection
for further characterization.
Extract ECC577 Is Predicted to Inhibit 30
mRNA Processing
Wescreeneda collectionof fermentationextracts to identifya sub-
set with intrinsic activity against bothC. albicans andA. fumigatus
(C.P. et al., unpublished data) and evaluated their potential MOA
by using CaFT profiling. Here, we focus on one such extract,
ECC577, derived from a culture broth of Fusarium larvarum
(MF7022), which inhibited growth of C. albicans, C. glabrata,
C. krusei, andA. fumigatus, but not bacterial pathogensStaphylo-
coccus aureus orEscherichia coli. CaFT profiling of ECC577 iden-
tifiedCLP1,PCF11, YSH1,PTA1,CFT2,MPE1, FIP1, ERG27, and
ORF19.7097 (C. albicans genome sequence Assembly 19 desig-
nation) heterozygotes to be reproducibly and statistically hyper-
sensitive (z-scoresR 3.5) over a range of growth-inhibitory con-
centrations tested (Figures 2A and 2C). Additionally, CFT1 and
YTH1 heterozygotes displayed significant hypersensitivity to
ECC577, albeit under only a single growth-inhibitory concentra-
tion. Excluding ERG27, all of these hypersensitive strains corre-
spond to genes encoding subunits of the eukaryotic mRNA C/P
complex (Figure 2B) (Proudfoot, 2004; Zhao et al., 1999).
ORF19.7097 is homologous to the bovine polyadenylate-binding
protein 2 (PABP2), which stimulates PAP activity by enhancing
its binding affinity for the mRNA substrate (Kerwitz et al., 2003).
In addition, multiple heterozygote strains corresponding to RNA
polymerase II (RNAPII) activity (including RPO26, RPB7, and
RPB8) and ribosomal biogenesis (NOC3, NUG1, NOP14, and
UTP22) reproducibly displayed an apparent resistant phenotypeAll rights reserved
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the bioactive component present in extract ECC577 may inhibit
growth by interfering with mRNA C/P functions.
The CaFT Profile of Cordycepin, a Known Inhibitor
of Poly(A) Polymerase Activity
To further characterize ECC577, we first compared its profile to
the CaFT profile of a known 30 mRNA processing inhibitor, cordy-
cepin (30-deoxyadenosine), which is a toxic adenosine analog
produced by Cordyceps militaris. Cordycepin is a pro-drug:
upon entering cells, it is converted to 30-dATP, which acts as
both an RNA molecule chain terminator and a substrate compet-
itive inhibitor of the PAP (Muller et al., 1977). CaFT profiles of cor-
dycepin were found to be highly related to those of extract
ECC577, with multiple components of the mRNA C/P complex
(CLP1, PCF11, YSH1, PTA1,CFT1) similarly displaying heterozy-
gote sensitivity in at least two of the drug concentrations tested
(Figures 2A and 2C). Additional strain depletions included DAL5
and FOL2. PAP1, which encodes PAP, was conspicuously
absent from either ECC577 or cordycepin CaFT profiles. As
this could reflect technical issues regarding PAP1 bar codes
(see Discussion), we tested whether PAP1 heterozygotes and/
or other subunits of the C/P complex are hypersensitive to
ECC577 and/or cordycepin. Individual heterozygotes compris-
ing the above-described CaFT profiles (including PAP1) were
directly evaluated by spot tests and were confirmed to be hyper-
sensitive to ECC577 and cordycepin (Figure 2D).
Noteworthy are two heterozygote strains (ADO1andNNT1) that
exhibit significant resistance to cordycepin and are unique to its
CaFT profile.ADO1 (adenosine kinase) is required to convert cor-
dycepin to 30-dAMP in vivo, and the ado1 null mutant of S. cerevi-
siae is resistant to cordycepin (Lecoq et al., 2001).NNT1 codes for
a Na+-independent, H+-coupled nucleoside symporter (absent in
S. cerevisiae) with broad nucleoside substrate specificity (Rodri-
guez-Suarez et al., 2007; Xu et al., 2007), including cordycepin
Figure 1. CaFT Profiling of Natural-Product
Crude Extracts
(A–C) CaFT profiles of purified (A) cerulenin, (B)
tunicamycin, and (C) brefeldin A versus crude
extracts of fermentation broths containing the
corresponding natural-product activity. Growth-
inhibitory concentrations are indicated. The
z-scores are displayed one-dimensionally regard-
lessofheterozygousstrain identities. Colorsymbols
designate heterozygote strains whose hypersensi-
tivities correspond to the MOA of the tested
compounds (see Xu et al., 2007 for details).
(Loewen et al., 2003). Presumably, hetero-
zygote levels of C. albicans NNT1 and
ADO1 reduce cordycepin uptake and its
conversion to 30-dATP, respectively,
thereby partially alleviating its growth-
inhibitory effects.
Interestingly, heterozygotes corre-
sponding to RNAPII that were hyposensi-
tive to ECC577 were not detected in cordy-
cepin CaFT profiles. These differences
predict that the MOA of ECC577 and cordycepin, while related,
are not identical. Importantly, thesedata alsopredict that the bioac-
tivecomponent withinECC577 isstructurallydistinct fromcordyce-
pin, since only cordycepin requires a nucleoside permease for up-
take. Indeed, LCMSanalyses of the ECC577 extractdid not identify
cordycepin or other potential nucleoside analogs (data not shown).
Isolation and Structure Elucidation of Parnafungin
To identify the active component in ECC577, a large-scale fer-
mentation of MF7022 was performed, and an acetone extract
of this material was used to confirm its original bioactivity by
using CaFT profiling (Figures 2A and 2C). Bioactivity-guided pu-
rification and structure elucidation were performed by X-ray
crystallography and NMR analysis (C.P. et al., unpublished
data), revealing a mixture of diastereomers (Figure 2E). CaFT
profiling of this purified diastereomer mixture reproduced the
CaFT profile of the crude extract (Figures 2A and 2C). Based
on its predicted MOA from chemical-genetic profiling, we have
named this compound class parnafungin (poly(A) RNA fungin).
The structural novelty of parnafungin resides in the presence of
an isoxazolidinone ring not previously reported, to our knowledge,
innatural products. It is fused toa xanthone ring systemcommonly
found in natural products, most notably in secalonic acids. Al-
though secalonic acids display broad antimicrobial activity (Reddy
and Reddy, 1991) and are potent inhibitors ofC. albicans, its CaFT
profile is unrelated to parnafungin (Table S1). Moreover, a deriva-
tive of parnafungin, in which the isoxazolidinone ring was opened
due to degradation, does not inhibit the growth of Candida sp.
(data not shown). Thus, the combined structural features of parna-
fungin are required for its antifungal activity and selectivity.
Biochemical Characterization of Parnafungin: A Potent
Inhibitor of 30 mRNA Polyadenylation
Consistent with its predicted MOA, parnafungin-treated
C. albicans cells show depleted poly(A)+ RNA transcript levelsChemistry & Biology 15, 363–374, April 2008 ª2008 Elsevier Ltd All rights reserved 365
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PAP Inhibitor with In Vivo Antifungal EfficacyFigure 2. CaFT Profiling of Parnafungin-Containing Extracts versus Cordycepin and Parnafungin Pure Compounds
(A) CaFT profiles of the Fusarium larvarum original crude extract (ECC577), its regrowth extract, purified parnafungin, and cordycepin. Six representative CaFT
experiments of parnafungin (two each for the original and regrowth extracts and purified compound) and three of cordycepin were combined for comparison. The
z-scores are displayed one-dimensionally regardless of heterozygous strain identities. Color symbols designate heterozygote strains whose hypersensitivities
correspond to the MOA of the tested compounds. CFI, cleavage factor I; CPF, cleavage and polyadenylation factor; CFII, cleavage factor II; PFI, polyadenylation
factor I.
(B) A schematic representation of the yeast C/P complex (adapted from Zhao et al., 1999, also see the reference for cis-acting elements in the precursor RNA).
Highlighted in red are the genes whose corresponding heterozygous strains are hypersensitive to parnafungin. CFII subunits are shown in light blue, and PFI
subunits are shown in green.
(C) Table representation of the CaFT profiles shown in (A). The most significant responsive heterozygous strains were selected based on the average of their
z-scores (R3.000 for hypersensitivity or%3.000 for resistance) in either of the two sets of experiments. The corresponding genes are grouped according to
their cellular functions and the possible relevance to the MOA of parnafungin and cordycepin. Also included (with orf19 designations and genes highlighted
in gray) are z-scores of strains that correspond to additional proteins involved in the 30-end processing but displaying no significant responses in the CaFT
experiments.
(D) Validationof the CaFT results by spot tests.Based on the CaFT results shown in (A), representative heterozygous deletion strains were selected (fromeach group)
and tested against parnafungin and cordycepin at multiple concentrations on the YNBD agar media (supplemented with CSM, 2-day growth at 30C). Also included
is the controlHIS3 strain, which is the cogenic parent of all heterozygous strains used in this study. Note that the two alleles ofPAP genes (red) are named according
to their chromosomal location adjacent to the mating-type-like loci. Although a PAPa/papaD strain is present in the CAFT pool, a PAPa/papaD strain is not.
(E) Structures of parnafungin A and B.(Figure S2). Since parnafungin is also active against S. cerevisiae
(see below), we employed an in vitro C/P assay with a yeast ex-
tract as previously described (Chen and Moore, 1992). Incuba-
tion of a 33P-labeled precursor RNA substrate with the yeast ex-
tract resulted in proper C/P (Figure 3B, lane 2), the latter of which
was efficiently blocked in the presence of 30-dATP (Figure 3B,
lane 3). The incorporation of 30-dATP (cordycepin triphosphate)366 Chemistry & Biology 15, 363–374, April 2008 ª2008 Elsevier Ltdterminates polyadenylation due to the lack of a 30-OH group
(Muller et al., 1977). Parnafungin inhibited the accumulation of
polyadenylated RNA product in a concentration-dependent
manner, with concomitant accumulation of the cleaved interme-
diate (Figure 3B, lanes 5–8). In the presence of 30-dATP, the
cleavage of precursor RNA was not significantly impaired by
parnafungin (Figure 3B, lanes 9 and 10).All rights reserved
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siae Pap1p and tRNA (Lingner et al., 1991), parnafungin was
a potent inhibitor with an IC50 of 66 ng/ml (145 nM) (Figure 3C).
In the PAP assays using a poly(A) substrate, parnafungin in-
hibited native C. albicans PAP activity and the recombinant
Papa enzyme with IC50 values of 14 and 10 ng/ml (31 and
22 nM), respectively. However, parnafungin also inhibited the
recombinant human PAP enzyme at an IC50 of 52 ng/ml
(114 nM). Thus, chemical modification of parnafungin would
be required to achieve further target selectivity. Nonetheless,
it was not a general inhibitor of nucleotide polymerase, as
the IC50 against three human DNA polymerase isoforms was
> 50 mM (data not shown). Furthermore, parnafungin is not an
ATP-competitive inhibitor of PAP activity (Figure 3D).
Isolation and Characterization of C. albicans PAP
Mutations that Confer Parnafungin Resistance
To corroborate the inhibitory activity of parnafungin on the
PAP enzymes, we performed chemical mutagenesis directly in
C. albicans to isolate PAP mutations that confer resistance to
the inhibitor. As the PAP gene is physically located in the MAT-
like loci of the genome, and its two alleles encode isoforms shar-
ing70% amino acid identity (Hull and Johnson, 1999), a hetero-
zygous deletion strain of PAPa/papaD and a control HIS3/his3D
strain were first used to generate parnafungin-resistant mutants.
After two rounds of selections, 80 and 8 resistant mutants were
obtained from these 2 strains, respectively. They were coun-
terscreened for resistance to fluconazole and aureobasidin A
(data not shown). Only seven mutants isolated from the PAPa/
papaD strain were resistant specifically to parnafungin. From
these mutants, the entire PAPa ORFs were PCR amplified and
cloned. DNA sequence analyses revealed that strains CA62,
CA72, and CA75 contain a single nucleotide alteration in the
PAPa gene. This T-to-A mutation resulted in an amino acid sub-
stitution from Phe to Ile in residue 115 located in the conserved
nucleotidyl-transferase domain of PAP proteins (Figure 4A). No
mutation in PAPa was found in 16 additional crossresistant
mutants in the background of the PAPa/papaD strain (data not
shown).
As the surviving cells after the mutagenesis were plated di-
rectly on parnafungin-containing media, papa(F115I) mutations
arose independently. To determine if it is sufficient to confer
resistance to parnafungin, we introduced papa(F115I) into the
parental PAPa/papaD strain by two-step gene replacement
(Figure S3A). After integration of a functional papa(F115I) gene
(marked by URA3) at the PAPa locus, the resulting strain
(CA153, with two tandem PAP genes flanking URA3, PAPa::
URA3::papa(F115I)), showed intermediate resistance to parna-
fungin (Figure 4B), suggesting that the mutation is semidomi-
nant. After counterselection on 5-FOA, a single PAP allele was
retained. We confirmed that all of the parnafungin-resistant iso-
lates examined contained papa(F115I), whereas the sensitive
ones were wild-type (Figure 4B; Figure S3B). By the same
method, we introduced the corresponding mutation in PAPa in
a PAPa/papaD strain, and we determined that papa(F115I) also
confers resistance to parnafungin, is semidominant, and likewise
shows no crossresistance to other antifungals tested (Figure 4B
and data not shown). These results established that the F115I
change in either C. albicans PAP isoform is sufficient to alter sus-Chemistry & Biologceptibility to parnafungin. No significant resistance to cordyce-
pin was observed among assayable papa(F115I) or papa(F115I)
mutants (Figure 4C). We conclude that the F115I substitution
specifically confers parnafungin resistance to both PAP
isoforms.
In Vitro Microbiological Activity of Parnafungin
Parnafungin whole-cell potency was assessed against a panel of
clinically relevant fungal and bacterial pathogens (Table 1).
Parnafungin is markedly potent against C. albicans, and it dis-
plays a minimal inhibitory concentration (MIC) of 14 ng/ml and
equivalent potency against clinical and laboratory isolates of
C. albicans with reduced susceptibility to caspofungin (e.g.,
CLY1996) (Park et al., 2005). While parnafungin is less potent
against two fluconazole-resistant C. albicans clinical isolates
(Safdar et al., 2001), MICs remain below 1 mg/ml. Parnafungin ac-
tivity against five additional Candida sp. ranged between MIC
values of 0.014 and 3.33 mg/ml. Although A. fumigatus is less
susceptible to parnafungin (MIC = 8–16 mg/ml) (Figure 5A),
A. fumigatus PAP1 and CFT2 conditional mutants (see below)
displayed marked hypersensitivity to parnafungin under partially
repressing conditions without altered susceptibility to itracona-
zole (Figure 5B). Consistent with a eukaryotic-specific MOA, par-
nafungin did not inhibit the growth of either S. aureus or E. coli at
the highest concentration tested (Table 1).
Multiple Components of the Fungal Cleavage
and Polyadenylation Complex Are Essential
for Growth of C. albicans and A. fumigatus
PAP1 and each of 14 core subunits of the C/P complex are
essential for S. cerevisiae viability (Zhao et al., 1999). To test
whether their essentiality is conserved in fungal pathogens, we
constructed conditional mutants for 13 predicted orthologs in
C. albicans and A. fumigatus by using tetracycline (Tet)- and
nitrate (NiiA)-regulatable promoter replacement strategies previ-
ously described (Hu et al., 2007; Roemer et al., 2003). An exam-
ination of their terminal phenotype under repressing conditions
reveals that PAP and all 12 subunits tested are essential for
C. albicans viability (Figure S4). A. fumigatus PAP1 as well as
10 of 12 predicted C/P orthologs (Table S2) were also experi-
mentally confirmed to be essential (Figure S5). As the Tet- and
NiiA-regulatable promoters are also effectively repressed
in vivo, we tested the consequences of PAP shut-off in a mouse
model of candidiasis and aspergillosis, and we demonstrated
both pathogens to be avirulent upon genetic inactivation of
PAP1 in vivo (Figures 6A and 6B).
Efficacy of Parnafungin in a Murine Model
of Disseminated Candidiasis
Parnafungin’s potency against C. albicans, even in the presence
of 50% mouse serum (MIC = 1.111 mg/ml) (Table 1), as well as the
requirement for PAP1 to support cell growth and virulence in an
animal host suggest that parnafungin could display efficacy in an
animal model of infection. To evaluate its efficacy, C. albicans-
infected mice were treated at varying parnafungin doses twice
daily for 2 d in an abbreviated candidiasis model (Bartizal
et al., 1992), and on the day after the final compound treatment,
fungal burden was quantified within kidneys. The observed fun-
gal burden in sham-treated animals reached > 6.3 log10 CFU/gy 15, 363–374, April 2008 ª2008 Elsevier Ltd All rights reserved 367
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(A) Schematic representation of 30 mRNA processing.368 Chemistry & Biology 15, 363–374, April 2008 ª2008 Elsevier Ltd All rights reserved
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parnafungin displayed a significant and dose-dependent de-
crease in fungal burden (Figure 6C). At a dose of 50 mg/kg, the
fungal burden decreased by 2.30 and 2.88 log10 CFU/g kidney.
The dose capable of reducing C. albicans burden by >99%
(ED99) was 30.98 and 20.82 mpk, respectively, and no adverse
(B) In vitro assay of C/P using the whole-cell extract (WCE) prepared fromS. cerevisiae. The 33P-labeled precursor RNA (lane 1) was incubated with the WCE under
various conditions for the production of poly(A)+ product (lane 2), the 50 portion of the intermediates (lane 3, with the polyadenylation reaction blocked by 30-de-
oxyl-ATP), and both 50- and 30-intermediates (lane 4). Parnafungin, at the concentrations indicated, was added to the reaction under the standard conditions (lanes
5–8), or in the presence of 30-deoxyl-ATP (lanes 9 and 10). Note that under the standard conditions poly(A)+ product was diminished, and that there was simul-
taneous accumulation of the 50-intermediate with increasing concentrations of parnafungin (lanes 5–8), suggesting a preferential inhibition of polyadenylation.
Moreover, in the presence of 30-deoxyl-ATP, which blocks polyadenylation (lanes 3), the accumulation of the 50-intermediate was also diminished, suggesting
a partial inhibition of the cleavage by parnafungin.
(C) Inhibitory effects of parnafungin on polyadenylation of tRNA and poly(A) RNA substrates catalyzed by the indicated PAP enzymes from S. cerevisiae,
C. albicans, and human sources.
(D) Titration of competitive inhibitors of PAP (a, b methylene ATP, Ap4A) and parnafungin against ATP (at 6 and 60 mM) in an in vitro polyadenylation assay with
recombinant S. cerevisiae Pap1p and poly(A) RNA.
Figure 4. Isolation and Characterization of C. albicans PAPa and PAPa Mutations Conferring Parnafungin Resistance
(A) The domain structure of PAP (top) and the alignment of the amino acid sequence of a portion (indicated by the hatched bar) of the NTP transferase domain of
PAPs (bottom) from C. albicans (GenBank accession numbers are provided in the Supplemental Experimental Procedures). The parnafungin-resistant mutations
in Papap and Papap are indicated.
(B) Susceptibility of relevant strains to parnafungin (on YNBD agar media, supplemented with 2.5 mM uridine), including: a control strain (CA12), the parental
heterozygous deletion strain (CA35) used in EMS mutagenesis, and three independent original resistant isolates (CA62, 72, 75) containing the papa(F115I) mu-
tation. The starting strains used in the two-step gene replacement are CA413 and CA226, derived from CA35 and CA225, respectively. The pop-in (CA153, 227)
and pop-out (CA164, 229) strains are indicated by their genotypes.
(C) Susceptibility of papa(F115I)- and papa(F115I)-containing mutants to cordycepin. Reconstructed mutant strains are ura3 and require uridine, which, as
a competitive substrate for the transporter Nnt1p, suppresses cordycepin (data not shown). Thus, they were not examined for cordycepin susceptibility. Instead,
the URA3 prototrophs (CA62, 72 and 75) and the two pop-in strains (CA153 and 227) were tested. Shown is the 2-day growth on YNBD agar media at 30C.Chemistry & Biology 15, 363–374, April 2008 ª2008 Elsevier Ltd All rights reserved 369
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groups. As the genetic inactivation of PAP under all candidiasis
experimental conditions tested (Figure 6A) resulted in a fungal
burden often below or near the limit of detection (Table S3),
chemical optimization of parnafungin may significantly improve
its efficacy. ED99 values for the FDA-approved antifungal agents
caspofungin and fluconazole were 0.033–0.038 mpk and
0.933–1.004 mpk, respectively.
DISCUSSION
We screened a defined set of C. albicans heterozygote deletion
mutants largely representing genes required for viability and/or
normal growth for their altered sensitivity to growth-inhibitory
compounds to identify small molecules that act by a target-
specific mechanism. The discovery of parnafungin demon-
strates that crude fermentation extracts are assayable and that
mechanistically informative chemical-genetic profiles are
derived from naturally produced bioactive compounds within
complex mixtures. Parnafungin’s MOA was verified by both bio-
chemical and genetic means, and its further characterization
supports its potential as a new antifungal agent with a unique
MOA.
Mechanism-of-Action Profiling of Crude Extracts
Despite the intrinsic challenges of evaluating natural-product
extracts, CaFT profiling and upfront MOA annotation of crude
extracts may provide a powerful approach to screening and
selecting appropriate samples for chemical isolation. Thus, by
screening a breadth of potential drug targets, diverse MOAs
may be revealed among distinct extracts, and those predicted
Table 1. The Whole-Cell Inhibitory Activity of Parnafungin
Species Strain MIC (mg/ml)a
C. albicans MY1055 0.014
C. albicans
(50% mouse serum)
MY1055 1.111
C. albicans CLY16996b 0.014
C. albicans CLY16998c 0.014
C. albicans JMB4d 0.041
C. albicans 395-98e 0.123
C. glabrata ATCC90030 1.111
C. parapsilosis ATCC220129 1.111
C. lusitaniae ATCC34449 1.111
C. krusei ATCC6258 0.014
C. tropicalis ATCC750 3.333
S. cerevisiae ATCC201389 3.333
S. aureus MB2865 >32
E. coli ATCC25922 >32
a MIC was determined in Sabarose Dextrose medium.
b The clinical isolate that contains a mutation in fks1 and is resistant to
Candidas (Bartizal et al., 1992).
c The clinical isolate from the same patient with a wild-type FKS1.
d Clinical isolate with fluconazole resistance due to overexpression of
MDR1 (D. Perlin, personal communication).
e Clinical isolate with fluconazole resistance due to overexpression of
CDR1, CDR2, and MDR1 (D. Perlin, personal communication).370 Chemistry & Biology 15, 363–374, April 2008 ª2008 Elsevier Ltdto affect preferred cellular processes/targets may be prioritized
accordingly. Here, we focused on an extract predicted to affect
30 mRNA maturation, as this process is broadly conserved in eu-
karyotes and is essential for cell growth among pathogenic fungi
(Table S2). As such, the bioactive component is predicted to dis-
play broad antifungal activity. Similarly, new or known natural
products affecting clinically validated antifungal targets, includ-
ing cell wall and ergosterol biosynthesis, may be identified and
prioritized for follow-up evaluation (unpublished data). Impor-
tantly, as bioactive natural products often generally disrupt cell
membranes (e.g., polyenes, ionophores), alkylate DNA synthesis
(e.g., rachelmycin/CC1065), or impair RNA synthesis (actinomy-
cins), rather than inhibit specific protein targets, such extracts
could be avoided. A compendium of chemical-genetic profiles
has been used to predict MOA of previously characterized com-
pounds among others that display related profiles (Hughes et al.,
2000; Parsons et al., 2006). Here, we demonstrate that new
chemical matter with mechanistically defined activity can be dis-
covered. By using even a small reference set of mechanistically
significant natural-product profiles, the relatedness of CaFT
profiles produced from an undefined crude extract can be
compared to the reference set to predict its bioactivity.
Biology
Interestingly, the C. albicans PAP gene encodes isoforms shar-
ing only 70% amino acid identity (Hull and Johnson, 1999). De-
spite such extreme polymorphisms, we demonstrate that both
alleles, PAPa/papaD and PAPa/papaD, are functional as hetero-
zygote deletion mutants, display normal growth rates, and are
collectively essential, as the Tet-PAPa/papaD conditional mu-
tant is not viable under Tet-repressing conditions (Figure S4).
Parnafungin likely inhibits both PAP isoforms, as both PAPa/
papaD and PAPa/papaD heterozygotes are hypersensitive to
drug treatment (with the PAPa/papaD heterozygote particularly
hypersensitive), and F115I mutations in either PAP allele confer
resistance (Figure 4). Surprisingly, CaFT profiles did not identify
the PAP heterozygote as sensitive to either the parnafungin-con-
taining extract or the pure compound. This is due to suboptimal
PAP barcodes, which provide low hybridization levels and large
standard deviations between experiments (data not shown). In-
deed, the predicted MOA for parnafungin (and cordycepin)
was not based on the identification of PAP within the CaFT pro-
file, but rather on the chemical sensitivity of a functional network
of genes encoding subunits of the C/P complex and 30mRNA
processing (Figure 2). We speculate that the biological richness
of these profiles reflects synthetic lethal interactions between
chemical inhibition of PAP and the heterozygosity of other es-
sential subunits of the C/P complex. Parnafungin may also indi-
rectly affect assembly, stability, and/or function of the C/P com-
plex through its inhibition of PAP, as weak effects on 30 mRNA
cleavage were also observed in the cell-free C/P assay despite
biochemical and genetic evidence supporting the idea that
PAP-mediated polyadenylation is its primary target.
Chemical-genetic profiles of parnafungin and cordycepin also
emphasize the important interrelationships between mRNA
transcription, its 30 processing, and degradation. For example,
mRNA C/P processing is coupled to its transcription via the
C-terminal domain (CTD) of Rpo21p, the largest subunit of RNA-
PII (Proudfoot et al., 2002; Proudfoot, 2004; Zhao et al., 1999).All rights reserved
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and cordycepin profiles (despite its inclusion in the strain set),
other heterozygotes of subunits of the RNAPII complex (RPB8,
RPO26, and RPB7), whose gene products physically interact
with the Rpo21p CTD, were resistant to parnafungin. This may
reflect a mechanism whereby subtly impairing mRNA transcrip-
tion in RNAPII heterozygote strains can partially ameliorate com-
pound inhibitory effects on 30 mRNA processing, thereby restor-
ing a biosynthetic balance between both processes. Although
the C/P complex is well characterized in both yeast and meta-
zoans (Proudfoot et al., 2002), the identity of its endonuclease
has remained elusive, and only recently has Ysh1p and its human
Figure 5. Antifungal Activity of Parnafungin
against A. fumigatus
(A) Susceptibility of the wild-type strain (CEA10,
opened circle) and a pNiiA-AfPAP1 (PAP1) strain,
under the inducing conditions (10 mM Mg(NO3)2,
I, opened triangle) and the partially repressing
conditions (5 mM Mg(NO3)2 and 5 mM ammonium
tartrate, PR, filled triangle) in AMM liquid medium.
The percentage of growth was normalized with
that of CEA10 in the absence of parnafungin.
(B) A. fumigatus PAP1 and CFT2 conditional
mutants are selectively hypersensitive to parna-
fungin. pNiiA-AfPAP1 and pNiiA-AfCFT2 strains
were grown under inducing or partially repressing
conditions (as indicated by the concentrations of
Mg(NO3)2 (NO3) and ammonium tartrate (NH4))
with antifungal compounds added directly on the
seeded agar. White spots within the zone of inhibi-
tion are due to compound precipitation. Itracona-
zole is included as a control.
counterpart (CPSF-73) been implicated to
confer this function (Ryan et al., 2004). As
the YSH1 heterozygote is the most signif-
icantly hypersensitive component of the
C/P complex, it may be uniquely super-
sensitive to parnafungin since both endo-
nuclease and polyadenylation activities
would be impaired by heterozygosity
and chemical inhibition, respectively. Fi-
nally, POP2 encodes an mRNA deadeny-
lase required for degradation of polyade-
nylated transcripts in yeast (Daugeron
et al., 2001), and a C. albicans POP2
heterozygote displayed resistance to
both parnafungin and cordycepin. There-
fore, attenuated mRNA deadenylation by
POP2 heterozygosity may partially reme-
diate the effects of chemical (or genetic)
inactivation of PAP.
Chemical-genetic profiles, however,
provide only a hypothesis as to the MOA
of bioactive natural products, and bio-
chemical and/or genetic confirmation of
such predictions are required. To this
end, we demonstrate that parnafungin
principally effects 30 mRNA polyadenyla-
tion in a yeast cell-free system, and that C. albicans, S. cerevi-
siae, and human PAP enzymes are all inhibited by parnafungin,
but with C. albicans PAP displaying a 4- to 5-fold lower IC50 to
the compound (Figure 3). We also demonstrate that a F115A
substitution in either C. albicans PAP allele is sufficient to specif-
ically confer parnafungin resistance (Figure 4; Figure S3). Al-
though, this mutation maps to the ATP-binding domain of PAP,
parnafungin does not act as an ATP-competitive inhibitor. Im-
portantly, the in vitro parnafungin IC50 values against C. albicans
PAP strongly correlate with its MIC against this pathogen, rein-
forcing its primary MOA in whole cells. The lack of a similar cor-
relation between the in vitro and in vivo inhibitory effects ofChemistry & Biology 15, 363–374, April 2008 ª2008 Elsevier Ltd All rights reserved 371
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Demonstrate PAP Target Essentiality and
Parnafungin Efficacy
(A) In vivo target validation of PAP1 in a murine
model of candidiasis. Mice were infected with
a pTET-PAPa/papaD strain and subjected to the
following treatments: solid circle, doxycycline
given to the mice starting 3 d before infection
(Dox-3, prophylactic treatment); open square,
doxycycline treatment started 2 d after the infec-
tion (Dox+2, symptomatic treatment); open circle,
sugar 5% (no doxycycline treatment control).
Twenty-one days after infection (indicated by an
arrow), all remaining mice stopped receiving doxy-
cycline and were given water instead, until the end
of the experiment at day 35 postinfection.
(B) In vivo target validation of PAP1 in an immuno-
compromised murine model of aspergillosis. open
circle, pNiiA-PAP1 strain; solid circle, wild-type
strain (CEA10), included as a control for virulence.
(C) In vivo efficacy of parnafungin in a systemic
model of candidiasis. Mice were treated in two in-
dependent experiments (1 and 2, filled and
opened bars, respectively) with parnafungin, cas-
pofungin, or fluconazole at the indicated doses
(mg/kg). Kidneys were aseptically extracted after
treatment, and log reduction in CFU/gm kidney
tissue was calculated based on kidney burden of
sham treatment. Note that the limit of detection
is 1.603 102 CFU/gm, as indicated by the dashed
line.parnafungin against S. cerevisiae remain unclear, but they may
reflect differences in drug uptake, efflux, and/or metabolism.
Similarly, differences in parnafungin metabolism by C. albicans
and mammalian cells may contribute to its efficacy in a murine
model of infection, despite potential issues of target-specific
toxicity.
Chemical-Genetic Profiling in C. albicans
and S. cerevisiae
Does it matter whether a C. albicans or S. cerevisiae-based
chemical genomics strategy is used? In the case of parnafungin,
as its C. albicans potency is more than 200-fold greater than
S. cerevisiae (Table 1), it was beneficial to apply the CaFT, partic-
ularly when screening it within a crude extract of low titer. How-
ever, other compounds displaying reversed relative potencies,
and favoring the use of yeast would be anticipated. It is also
true that NNT1, which is absent in S. cerevisiae, and its heterozy-
gote resistance to cordycepin, but not parnafungin, in CaFT pro-
files aided in discriminating between the known versus novel
compound and prioritizing its isolation. However, ADO1 and/or
RNAPII subunit heterozygote resistance in yeast would similarly
capture the distinction between parnafungin and cordycepin
profiles. A significant benefit to using a S. cerevisiae-based
chemical-genetic approach is that full genome coverage is
available in the heterozygote collection, thus ensuring that all
essential genes are included in analyses, and that the resource
is available to the community without restriction.
Chemical-genetic strategies offer powerful probes into the
immensity of natural chemical diversity. Genome-scale repre-
sentation of potential targets against the complexity of compo-
nents in even one microbial broth produces a multifactorial372 Chemistry & Biology 15, 363–374, April 2008 ª2008 Elsevier Ltincrease in the effective number of screens performed. Unlike
traditional HTS, in which individual ‘‘privileged’’ target(s) are
screened against large collections of individual compounds,
here potentially hundreds of compounds are screened against
thousands of targets in empiric fashion by evaluating a single
crude extract. Moreover, a greater understanding of compound
MOA can be achieved, reflecting not only its protein target, but
genetic and physical interaction networks of the target as well
as its metabolism. An important limitation to this approach,
however, applies to extracts containing multiple mechanisti-
cally distinct bioactive compounds. In such cases, only the
most prominent member contributing to the overall growth-
inhibitory activity of the extract (either due to its high titer or in-
creased potency) can be reliably assayed; minor but potentially
interesting activities would be masked in this way and over-
looked. Thus, a breadth of extracts may be screened, but the
depth in which they can be evaluated remains limiting without
chemical fractionation.
Natural products (beginning with penicillin) have made a sig-
nificant contribution to antibiotic discovery and provide a logical
starting point for identifying new antimicrobial compounds of
potential therapeutic utility. However, surprisingly few target-
specific and mechanistically characterized natural-product-de-
rived antifungal compounds have been discovered, and even
fewer display all of the critical attributes of an antifungal agent,
namely, a clear target-based MOA, favorable in vitro potency,
spectrum, and efficacy in an animal model of infection (Vicente
et al., 2001). The discovery of parnafungin by chemical-genetic
screening of natural product suggests that this approach
is likely to impact antimicrobial drug discovery and add to
the catalog of new bioactive small molecules that act byd All rights reserved
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proteome.
EXPERIMENTAL PROCEDURES
Chemicals, Reagents, and Strains
Reference compounds cerulenin, tunicamycin, brefeldin A, and cordycepin
were all purchased from Sigma-Aldrich (St. Louis, USA). Fluconazole (DiFlucan
Injection, NDC 0049-3371-26 Lot PS152207) was obtained from Pfizer.
Heterozygous deletion and conditional shut-off (Tet-regulatable) stains were
described previously (Roemer et al., 2003). They and parnafungin are available
for noncommercial use by following the standard Merck Material Transfer
Agreement (MTA) and clearance procedures.
C. albicans Fitness Test and Spot Tests
The C. albicans fitness test (CaFT) is described by Xu et al. (2007). A summary
of heterozygous strains present in the pool is provided in Table S1. Spot tests
and liquid assays were performed as described (Xu et al., 2007); specific con-
ditions are provided in legends. Although we are unable to provide the com-
plete heterozygote strain set at this time, we invite academic researchers to
contact us regarding possible collaborations related to MOA studies of bioac-
tive compound(s) of mutual interest. Following an MTA executed by both
parties, such compounds would be screened by the CaFT, and results would
be communicated to the collaborator.
Natural-Product Extracts
Fermentation broths derived from Sarocladium oryzae (cerulenin producer),
Eupenicillium brefeldianum (brefeldin A), Streptomyces lysosuperficus (tunica-
mycin), and Fusarium larvarum (MF7022; parnafungin) were grown in liquid
medium, extracted with an equal volume of acetone, and filtered. Acetone
was removed by blowing with nitrogen, and the aqueous material was exam-
ined by CaFT at sub-MICs ranging from IC30 to IC80. Isolation of parnafungin is
described by C.P., et al. (unpublished data).
Preparation of Whole-Cell Extract, (NH4)2SO4 Fractionation,
and In Vitro Cleavage and Polyadenylation Assay
The whole-cell extract (WCE) was prepared from S. cerevisiae by using the
method described by Chen and Moore (1992), with minor modifications that
protease inhibitors (1 mM PMSF, 2 mM pepstatin A, and 0.6 mM leupeptin)
were added to buffer C. The (NH4)2SO4 (40%) precipitate was dissolved in
and then dialyzed against buffer D. The final sample was frozen and stored
in 80C until use. The same method was used to prepare WCE from C. albi-
cans. The 33P-UTP-labeled RNA substrate was generated by in vitro transcrip-
tion of linearized plasmid pGAL7-1 by using T3 RNA polymerase as described
by Chen and Moore (1992). The standard C/P reaction (20 min at 30C) was
described by the same authors with minor modifications. Each reaction was
performed in a total volume of 10 ml, containing 20 mM HEPES (pH 7), 1 mM
Mn(CH3COO)2, 75 mM K(CH3COO), 2% PEG 8000, 1 mM ATP, 10 mM creatine
phosphate, 1 mM DTT, 8 U RNasin, and10 ng RNA substrate (33 106 cpm).
Extracted RNA product was resolved on a 6% denaturing gel and exposed to
a Phosphor Imager screen.
Poly(A) Polymerase Assay
The poly(A) polymerase (PAP) assays were as described by Lingner et al. (1991)
with modifications and recombinant S. cerevisiae PAP (USB). The reaction
(20 min at 30C) was performed in a 96-well format in a final volume of 20 ml,
containing 20 mM Tris (pH 7.0), 50 mM KCl, 0.7 mM MnCl2, 0.2 mM EDTA,
100 mg/ml BSA, 10% glycerol, 40 ng yeast tRNA (Sigma), 6 mM ATP,
0.075 mM 3H-ATP (GE/Amersham), and 50 U PAP, and was stopped by adding
150 ml 10% TCA and 10 mM Na4P2O7. The polyadenylated tRNA was captured
by GF/C glass filter paper, washed, and countered. A synthetic poly(A) RNA
(240 ng/reaction) (Sigma) was used in the native C. albicans PAP (from WCE,
0.5%) assay (0.8 mM ATP, 1.5 mM 3H-ATP, 20 mM creatine phosphate,
0.5 mM DTT, 0.1 mg/ml creatine kinase, 40 min at 30C). In assays with re-
combinant PAPs (6 mM ATP, 0.075 mM 3H-ATP), 9 ng C. albicans PAPa (with
200 ng poly(A), 15 min at 24C), or 10 ng human PAP (13 ng poly(A), 20 min
at 37C) was used.Chemistry & BiologIsolation and Characterization of Parnafungin-Resistant Mutants
EMSmutagenesiswasperformed according toGuthrieandFink (1991). Cultures
of the PAPa/papaD (CA35) and theHIS3/his3D (CA12) strains were treated with
EMS at a survival rate of10%. The surviving cells were plated directly on YNBD
agar containing 100 ng/ml parnafungin. A total of 33 107 and 13 107 surviving
cells from CA35andCA12 strains, respectively,were screened.After two rounds
of selection, the resistant isolates were tested for resistance to fluconazole (at 2
and 4 mg/ml) and aureobasidin A (at 20, 30, and 40 ng/ml). The entire coding se-
quences of PAPa from selected mutants were PCR amplified, cloned, and fully
sequenced. A two-step gene replacement strategy (Guthrie and Fink, 1991) was
used to introduce apapa(F115I) chromosomal mutation in CA35 (see Figure S3A
fordetails).Thepop-in transformants (e.g., CA153,containing tandem repeatsof
papa(F115I)::URA3::PAPa) were selected, and correct integration was con-
firmed by PCR. They were subsequently selected for the loss of papa or
PAPa. The corresponding ORFs from the resulting pop-out strains were PCR
amplified, cloned, and sequenced. Those containing papa(F115I) (e.g.,
CA164, derived from CA153) orPAPa, together with the parental pop-in strains,
were tested for susceptibility to parnafungin (Figure S3B). The papa(F115I) mu-
tation was constructed by site-directed mutagenesis (QuickChange, Strata-
gene). It was introduced into thePAPa/papaD strain (CA226) in a similar manner.
C. albicans and A. fumigatus Virulence Studies
The murine model of systemic candidiasis was described by Roemer et al.
(2003). Three groups of ICR mice were each infected by tail-vein injection (106
cells of the pTET-PAPa/papaD strain) and were examined: (1) Dox-3, receiving
the doxycycline treatment 3 d (in the drinking water, at 2 mg/ml and 5% sucrose)
prior to infection; (2) Dox +2, receiving the doxycycline treatment 2 d after infec-
tion; and (3) the control, receiving only 5% sucrose for the duration of the exper-
iment. After 21 d postinfection, two mice from each group were taken for nec-
ropsy, and the remaining mice were switched to water. The survival of these
mice was monitored for an additional 2 weeks, and additional necropsies
were performed thereafter. The virulence of the pNiiA-PAP1 A. fumigatus mu-
tant was assessed in a murine model for systemic aspergillosis as described
previously (Hu et al., 2007). All experiments were performed according to the
National Institutes of Health guidelines for the ethical treatment of animals.
In Vivo Efficacy Evaluation of Parnafungin
To evaluate parnafungin in vivo activity, a previously described model of dis-
seminated candidiasis with hypersusceptibility to C. albicans and increased
sensitivity for discriminating antifungal efficacy was used (Bartizal et al.,
1992). Immunosuppressed DBA/2N mice were challenged intravenously with
either 7.6 3 104 (experiment 1) or 3.0 3 104 (experiment 2) C. albicans
MY1055 and treated with 50, 25, or 12.5 mg/kg parnafungin (4 mice/group)
administered intraperitoneally twice daily over 2 d (4 doses). Fluconazole
and caspofungin were used as controls, and 10% DMSO was used as
a sham. After 48 hr, the mice were sacrificed, and burden of infection was
determined by cfu per gram of homogenized kidney.
SUPPLEMENTAL DATA
Supplemental Data include five figures, three tables, and a spreadsheet
containing the complete C. albicans heterozygote strain set as well as their
z-scores in all Fitness Test experiments described in the manuscript and are
available at http://www.chembiol.com/cgi/content/full/15/4/363/DC1/.
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